Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This was a retrospective cohort study which included all histologically proven cases of breast cancer in the 2 years from January 2022- December 2023 at a tertiary care centre.
This study was performed in line with STROCSS criteria. The following clinicopathological data was retrieved from the histopathological records- age, tumor size, nodal involvement, lymphovascular/ perineural invasion, and Bloom Richardson grading.
Routine histopathological processing was done followed by immunohistochemical analysis for ER, PR, HER2, Ki67 and AR. All the cases were categorised into Luminal A, B, Her2 enriched and triple-negative breast cancer based on the surrogate molecular classification. Further, all the cases were categorised into HER2 negative (no staining or incomplete weak membrane staining in ≤10% tumor cells), HER2 3+ (complete membranous staining) and HER2 low (1-2+ staining without amplification on ISH) based on consensus of two pathology consultants. The present study aims to evaluate the clinicopathological parameters of the HER2 low breast cancers.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HER2 low |
| ||
| HER2 negative |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| HER2 IHC | Diagnostic Test | Immunohistochemistry for HER2 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Age (in years) | It will be measured for HER2 low breast cancer patients | JANUARY 2022- DECEMBER 2023 |
| Tumor stage (categorised from T1-T4) | This denotes status of stage of tumor- T1, T2, T3, T4. It will be measured for HER2 low breast cancer patients | JANUARY 2022- DECEMBER 2023 |
| N stage (categorised from N0-N3) | This denotes status of nodal involevement- N0, N1, N2 or N3. It will be measured for HER2 low breast cancer patients | JANUARY 2022- DECEMBER 2023 |
| Tumor grade (categorised from G1-G3) | This denotes whether tumor is well, modeartely or porrly differentiated. It will be measured for HER2 low breast cancer patients. | JANUARY 2022- DECEMBER 2023 |
| Surrogate molecular classification (Categorised as luminal/ triple negative) | This denoted the molecular classification of breast cancer based on ER, PR, Her2 expression. | JANUARY 2022- DECEMBER 2023 |
| Androgen receptor expression (Denoted as present or absent) | This denoted the immunohistochemical expression of androgen receptor which would be evaluted in all cases of HER2 low breast cancer | JANUARY 2022- DECEMBER 2023 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
All histologically proven cases of breast cancer in the 2 years from January 2022- December 2023
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| VMMC SJH | New Delhi | India |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided